Latest Commercialization News

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Bisalloy Steel Group reported steady revenue but strong profit growth and a significant dividend increase for FY25, while outlining ambitious expansion plans for FY26.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

Core Lithium Ltd has launched a non-underwritten equity raising to secure approximately A$60 million, aiming to advance its Finniss Lithium Project to a final investment decision. The capital raise includes a two-tranche placement and a share purchase plan, supporting operational readiness and strategic funding efforts.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Orcoda Limited faced a challenging FY25 due to delayed projects from a key customer but is poised for recovery with new contracts and growth in recurring revenue. The company’s strategic diversification and AI-powered solutions underpin a confident outlook for FY26.